March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
2 Year Follow-up of Enhanced Induction/Maintenance Therapy for Neovascular Age-Related Macular Degeneration
Author Affiliations & Notes
  • David S. Dyer
    Retina Associates, PA, Shawnee Mission, Kansas
  • Michael P. Ellis
    Retina Associates, PA, Shawnee Mission, Kansas
  • Lindsey D. Dyer
    Retina Associates, PA, Shawnee Mission, Kansas
  • William J. Anderson
    Retina Associates, PA, Shawnee Mission, Kansas
  • Footnotes
    Commercial Relationships  David S. Dyer, Eyetech Pharmaceuticals (C); Michael P. Ellis, None; Lindsey D. Dyer, None; William J. Anderson, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 5171. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      David S. Dyer, Michael P. Ellis, Lindsey D. Dyer, William J. Anderson; 2 Year Follow-up of Enhanced Induction/Maintenance Therapy for Neovascular Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2012;53(14):5171.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To assess the long-term effectiveness and safety of an induction/maintenance regimen involving the sequential administration of nonselective and selective anti-vascular endothelial growth factor (VEGF) therapies in neovascular age-related macular degeneration (NV-AMD).

Methods: : A retrospective chart review of consecutive NV-AMD cases treated with an anti-VEGF induction/maintenance regimen for 24 months. Induction therapy with either intravitreal ranibizumab or bevacizumab was administered until there was no leakage on fluorescein angiography and/or no fluid on optical coherence tomography. Maintenance therapy with intravitreal pegaptanib 0.3 mg was to be administered every 6 weeks, with booster treatments of ranibizumab at the investigator’s discretion for worsening NV-AMD. Safety data was self-reported to nurses at the beginning of each visit. All clinical work was performed by one retina specialist at our multi-center retina practice.

Results: : In all, 154 eyes met criteria for inclusion in the analysis and received a mean of 3.5 ±1.3 induction and 11.4±2.4 maintenance injections. Preinduction to the last visit, 122/154 (79.2%) eyes avoided losing 3 or more lines and 40/154 (26%) gained 3 or more lines. Booster injections were required in 61/154 (39.6%) eyes. Safety data will be presented with the poster.

Conclusions: : A regimen involving an initial induction phase with nonselective anti-VEGF agents to eliminate retinal edema followed by maintenance pegaptanib was effective in maintaining visual acuity in NV-AMD. In addition, rates of serious systemic and ocular adverse events were low during the two years of treatment.

Keywords: age-related macular degeneration • vascular endothelial growth factor 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.